`
The global COVID-19 diagnostics market size was valued at USD 46.76 billion in 2021, making it one of the most rapidly expanded segments in modern healthcare history. Fortune Business Insights projects two divergent trajectories for the market through 2029:
- Scenario 1 (Endemic): Market declines from USD 23.79 billion in 2022 to USD 8.91 billion by 2029, reflecting a CAGR of -13.1%, assuming the pandemic transitions to an endemic phase.
- Scenario 2 (Cyclic Growth): Market falls more gradually from USD 48.64 billion in 2022 to USD 39.68 billion by 2029, at a CAGR of -2.9%, driven by recurring COVID-19 waves and new variants.
Key Market Drivers
Rising Caseloads & Testing Demand: The explosive growth in global COVID-19 infections created urgent, large-scale demand for diagnostic tools. With over 163.3 million people affected globally as of May 2021 (WHO data), demand for rapid, accurate testing surged. Governments and health agencies responded with large investments — the NIH alone committed USD 248.7 million in July 2020 to support new COVID-19 diagnostic technologies.
Product Innovation: Pharmaceutical and medical device companies rapidly developed novel kits and assays to meet the testing crisis. The U.S. FDA approved over 350 COVID-19 diagnostic tests, including 235 molecular, 34 antigen, and 88 antibody-based tests. By January 2022, approximately 700 tests were approved or available globally across North America, Europe, and Asia Pacific.
Point-of-Care Expansion: While RT-PCR remains the gold standard due to its accuracy, POC/rapid tests gained significant traction by offering results faster and at lower cost. By July 2021, more than 500 COVID-19 POC diagnostic tests were available globally. The U.S. Department of Health and Human Services invested over USD 560 million in October 2021 to support manufacturing and development of rapid diagnostic products.
Get a Free Sample PDF - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/covid-19-diagnostics-market-103291
Market Restraints
Despite strong growth, stringent regulatory frameworks presented challenges. Each country maintains its own regulatory authority — the FDA, CDC, and international equivalents — all requiring manufacturers to meet rigorous safety and efficacy standards before launching new kits, even under emergency conditions. Budget constraints across healthcare systems also moderated market growth potential.
Segmentation Insights
By Product: The instruments segment held the dominant share in 2021, while the reagents & kits segment is expected to register the highest growth rate, driven by continuous new product launches.
By Technology: PCR dominated in 2021, favored for high accuracy and cost-effectiveness. LFIA (Lateral Flow Immunoassay) holds the second-leading position, delivering results within 15 minutes. ELISA is growing steadily with rising FDA approvals.
By Sample Type: Oropharyngeal and nasopharyngeal swabs led the market, given their ease and speed of use. Nasal swabs held second place, while blood samples are gaining momentum for research applications including plasma therapy.
By Setting: Lab-based testing dominated in 2021 due to high-throughput capabilities. However, POC testing is projected to see the highest CAGR (Scenario 2), fueled by strong FDA emergency authorizations for bedside and home-based testing solutions.
By End-user: Laboratories and diagnostic centers held the dominant share. Under Scenario 2, the home testing segment is expected to overtake others, driven by consumer demand for rapid kits amid new variant outbreaks.
Regional Analysis
Europe led the global market in 2021, supported by its heavy COVID-19 caseload and proactive testing strategies. France alone reported 15.2 million cases by January 2022 (WHO). New product launches in the region further propelled growth.
North America recorded a market size of USD 11.97 billion in 2021, with robust growth expected under Scenario 2 due to increased diagnostic demand and strong regulatory infrastructure.
Middle East & Africa is anticipated to grow at the fastest CAGR during the forecast period, driven by rising adoption of detection instruments and kits.
Competitive Landscape
Abbott held the largest market share in 2021, backed by a broad product portfolio and key regulatory approvals such as the BinaxNOW COVID-19 Ag Self Test (FDA EUA, March 2021). The company reported a 21.8% revenue increase in 2021. F. Hoffmann-La Roche Ltd ranked as a close second, launching multiple products including the SARS-CoV-2 & Flu A/B Rapid Antigen Test. Other notable players include Danaher, Siemens Healthineers AG, Thermo Fisher Scientific, PerkinElmer Inc., bioMérieux SA, and Quest Diagnostics.
Conclusion
The COVID-19 diagnostics market reflects a sector shaped by crisis-driven innovation, regulatory responsiveness, and evolving public health needs. While the market is on a declining trajectory as acute pandemic pressure eases, its long-term trajectory depends heavily on the persistence of COVID-19 variants, public testing behavior, and the pace of endemicity — making it one of the most scenario-sensitive markets in global healthcare.
`
Top comments (0)